Elsevier

Drug and Alcohol Dependence

Volume 194, 1 January 2019, Pages 75-87
Drug and Alcohol Dependence

Methamphetamine use and cognitive function: A systematic review of neuroimaging research

https://doi.org/10.1016/j.drugalcdep.2018.08.041Get rights and content

Highlights

  • MA users showed poorer performance in all cognitive domains relative to controls.

  • Poor cognitive control in MA users is linked to deficits in the PFC and ACC.

  • Poor decision-making in MA users is linked to deficits in the PFC, ACC, and striatum.

Abstract

Background

Long-term use of MA has been associated with cognitive dysfunction in several domains. Neuroimaging studies have also reported structural, metabolic, and functional changes in MA users. However, no systematic review has been conducted on those studies in MA users that combined neuroimaging and cognitive tasks.

Methods

This article systematically reviews correlation between brain imaging measures and cognitive performance in subjects with current and previous history of MA use. Findings are categorized based on cognitive domain.

Results

MA users performed more poorly than controls in all cognitive domains (psychomotor, working memory, attention, cognitive control, and decision- making) and a positive correlation has been repeatedly observed between performance and brain measures (regional volume/density, blood flow, glucose metabolism, FA value, NAA level, and activation) in MA users. Performance in cognitive control was consistently reported to show relationship with brain measures in the PFC and ACC, while decision- making consistently showed correlation with brain measures in the PFC, ACC, and striatum.

Conclusions

There is solid evidence for brain- behavior relationship in cognitive functioning in MA users, particularly in cognitive control and decision-making. More research with correlation analysis between brain-behavior and MA use parameters is strongly encouraged.

Introduction

Amphetamines, a group of stimulants that includes amphetamine and methamphetamine (MA), are the second most abused worldwide after cannabis (United Nations Office on Drugs and Crime, 2017a). Global prevalence for amphetamines in 2015 was estimated to be 0.8%. In some parts of the world, the numbers are higher; prevalence in North America was 2.0% and in Oceania was 1.9%. The global market for amphetamines was dominated by MA, which accounted for 72% of the global seizures of amphetamines (United Nations Office on Drugs and Crime, 2017b).

Chronic MA abuse has been associated with an impaired cognitive function in several domains: attention, memory, and executive function (Kalechstein et al., 2003; Rendell et al., 2009; Simon et al., 2000). However, as the studies in MA individuals were cross-sectional, it is not possible to conclude that the cognitive deficits were MA-related. Animal studies have provided some evidence for the cognitive decline as the result of repeated MA administration; memory deficits have been observed in rodents (Kamei et al., 2006; Mizoguchi et al., 2011; Nagai et al., 2007; Noda et al., 2010) and impaired inhibitory control has been observed in monkeys (Groman et al., 2012). Study in twins also reported that amphetamine users had poorer performance on attention and psychomotor functions than their non-using twins (Toomey et al., 2003). Interestingly, one study has reported that, despite the higher rates of impairment in the MA group relative to controls in learning, psychomotor, and attention domains, impaired and normal MA subjects were comparable in all MA use parameters, such as age of first use, years of use, amount of use, and length of abstinence, suggesting the potential contribution of other factors, e.g., genetics (Cherner et al., 2010; Dean et al., 2013). Taken together, these findings support the notion that MA abuse causes cognitive decline, at least in some individuals (Dean et al., 2013).

Neuroimaging techniques have been used to study brain structure, metabolism, and function in MA users. Some regions have been reported to show significant differences between MA and control groups: cortical gray matter (GM), such as the prefrontal cortex (PFC) and the anterior cingulate cortex (ACC); subcortical GM, such as the striatum; and the frontal white matter (WM). In early studies using Positron Emission Tomography (PET), lower dopamine transporters (McCann et al., 1998; Sekine et al., 2001; Volkow et al., 2001c) and dopamine receptor availability (Lee et al., 2009; Volkow et al., 2001a), as well as lower serotonin transporter density (Sekine et al., 2006) have been observed in the striatal region in groups of MA subjects. Studies using Magnetic Resonance Imaging (MRI) have reported larger striatal volume (Jernigan et al., 2005) and smaller cortical volume in MA groups (Morales et al., 2012; Nakama et al., 2011). Meanwhile, studies using Magnetic Resonance Spectroscopy (MRS) in MA individuals have observed lower N-acetylaspartate (NAA) level, a proposed marker for neuronal integrity (Moffett et al., 2007; Sullivan et al., 2001), in the frontal WM and the ACC (Ernst et al., 2000; Nordahl et al., 2002; Sailasuta et al., 2010). Diffusion Tensor Imaging (DTI) studies have reported lower restricted diffusion or fractional anisotropy (FA) in frontal WM of MA groups (Alicata et al., 2009; Tobias et al., 2010). Lower restricted diffusion or higher apparent diffusion may indicate impaired WM integrity. Lastly, studies using Functional Magnetic Resonance Imaging (fMRI) have reported lower activation in the PFC and the ACC in groups of MA users during attention (Nestor et al., 2011) and decision-making tasks (Paulus et al., 2003; Stewart et al., 2014). Attenuated activation may reflect reduced resources to process information and may result in performance deficits.

Several articles have reviewed brain alterations and cognitive function in MA users. Salo and Fassbender (2012) reviewed neuroimaging studies (PET, MRI, MRS, DTI, and fMRI) conducted in long-term MA users and discussed relevant cognitive findings from MA and control groups. Another review by Jan et al. (2012a) focused on structural and functional imaging studies (PET, MRI, and fMRI) in MA abusers and the effect of abstinence on the brain measures. Hart et al. (2012) reviewed the findings from studies that assessed acute and long-term effects of MA use on cognitive functions and discussed relevant neuroimaging data (PET, MRI, DTI, and fMRI). While these reviews discussed neuroimaging and/or cognitive findings from MA subjects and controls, currently no review has been published on the relationship between cognitive function and brain measures in MA subjects. This review aims to fill the gap and systematically clarify the link between cognitive performance and brain measures, such as regional volume, glucose metabolism, NAA levels, FA values, and activation, in individuals with a history of MA or amphetamine abuse. In this review, we identify relevant studies using different imaging modalities such as PET, MRI, DTI, MRS, and fMRI. We believe that investigating the brain-behavior correlation will assist in understanding the neural mechanisms underlying cognitive impairment in MA individuals, providing data were available from different stages of MA abuse (e.g., recreational use, dependent use, early abstinence, and protracted abstinence). In addition, understanding the relationship between brain measures and cognitive function in MA users may help in identifying potential targets for MA abuse prevention and treatment. As the affected regions in drug addiction overlap with the regions involved in cognitive function, such as memory, cognitive control, and decision-making (Koob and Volkow, 2016; Schoenbaum et al., 2006), targeting these neurobiological circuits may help preventing transition from occasional to compulsive drug use, and may have clinical implications for preventing relapse (Hester et al., 2010; Suckling and Nestor, 2017; Verdejo-García et al., 2006).

Section snippets

Data source

Relevant articles were collected from three databases: Ovid, Scopus, and Web of Science between 1980 and January 2017. The search strategy was designed to retrieve as many studies as possible that were conducted using neuroimaging techniques and evaluated cognitive function in participants who were users or past users of MA. The search was performed using three groups of keywords: (1) terms related to cognitive function; (2) methamphetamine or amphetamine; and (3) terms related to neuroimaging (

Results

Twenty-nine studies met the inclusion criteria: 28 studies of MA users and 1 study of polydrug users (Koester et al., 2013). Two studies were performed in active-users (Jan et al., 2012b; Kim et al., 2016), while the rest were carried out with abstinent subjects (n = 27). The neuroimaging techniques used in these studies were PET (n = 6), MRI (n = 6), perfusion MRI (n = 1), DTI (n = 3), MRS (n = 3), and fMRI (n = 10). The included studies were assessed and grouped by cognitive domain:

Discussion

The main finding of this review is that there is a strong indication of the relationship between brain imaging measures and cognitive performance in MA users. In all cognitive domains, MA subjects showed poorer performance than controls. Qualitative comparisons across different imaging modalities showed that in the majority of cases, poorer performance was associated with deficits in the brain measures, such as lower metabolism, GM density, FA, NAA, and activation. In this discussion, deficits

Conclusions

Recent studies have provided some evidence for altered cognitive function in MA users in several domains, notably in cognitive control and decision-making. Consistent correlations have also been observed between performance on these functions and brain measures in some regions, particularly in the ACC, PFC, and striatum. Future research that investigates the relationship between the brain-behavior data and MA use parameters is essential to identify regions that are more vulnerable to the

Role of funding source

No funding was directly attained that supported this research. Sabrini Sabrini was supported by the Doctoral Scholarship, provided by LPSDM of Aceh Government, Republic of Indonesia.

Contributors

SS: Performed the systematic search, article retrieval, screening and analysis of the review. Also, was the lead author to write the manuscript. Approved the final version of the manuscript.

GYW: Was involved in drafting the objectives of the review, analysis, interpretation of results and writing of the manuscript. Approved the final version of the manuscript.

JCL: Was involved in the analysis, interpretation of results and writing of the manuscript. Approved the final version of the manuscript.

Conflict of interest

No conflict declared

Acknowledgements

No acknowledgements

References (81)

  • Y.T. Kim et al.

    Dose-dependent frontal hypometabolism on FDG-PET in methamphetamine abusers

    J. Psychiatr. Res.

    (2009)
  • G.F. Koob et al.

    Neurobiology of addiction: a neurocircuitry analysis

    Lancet Psychiatry

    (2016)
  • D.S. Leland et al.

    Anterior cingulate cortex and benefit of predictive cueing on response inhibition in stimulant dependent individuals

    Biol. Psychiatry

    (2008)
  • E.D. London et al.

    Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers

    Biol. Psychiatry

    (2005)
  • H. Mizoguchi et al.

    Nicotine ameliorates impairment of working memory in methamphetamine-treated rats

    Behav. Brain Res.

    (2011)
  • J.R. Moffett et al.

    N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology

    Prog. Neurobiol.

    (2007)
  • A.M. Morales et al.

    Gray-matter volume in methamphetamine dependence: cigarette smoking and changes with abstinence from methamphetamine

    Drug Alcohol Depend.

    (2012)
  • L.J. Nestor et al.

    Prefrontal hypoactivation during cognitive control in early abstinent methamphetamine-dependent subjects

    Psychiatry Res.

    (2011)
  • T.E. Nordahl et al.

    Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: a preliminary proton MRS study

    Psychiatry Res.

    (2002)
  • M.P. Paulus et al.

    Decision making by methamphetamine-dependent subjects is associated with error-rate-independent decrease in prefrontal and parietal activation

    Biol. Psychiatry

    (2003)
  • R. Salo et al.

    Behavioral regulation in methamphetamine abusers: an fMRI study

    Psychiatry Res.

    (2013)
  • R. Salo et al.

    Cognitive control and white matter callosal microstructure in methamphetamine-dependent subjects: a diffusion tensor imaging study

    Biol. Psychiatry

    (2009)
  • R. Salo et al.

    Spatial inhibition and the visual cortex: a magnetic resonance spectroscopy imaging study

    Neuropsychologia

    (2011)
  • R. Salo et al.

    Attentional control and brain metabolite levels in methamphetamine abusers

    Biol. Psychiatry

    (2007)
  • R. Salo et al.

    Impaired prefrontal cortical function and disrupted adaptive cognitive control in methamphetamine abusers: a functional magnetic resonance imaging study

    Biol. Psychiatry

    (2009)
  • G. Schoenbaum et al.

    Orbitofrontal cortex, decision-making and drug addiction

    Trends Neurosci.

    (2006)
  • D.L. Schwartz et al.

    Global and local morphometric differences in recently abstinent methamphetamine-dependent individuals

    Neuroimage

    (2010)
  • J.L. Stewart et al.

    You are the danger: attenuated insula response in methamphetamine users during aversive interoceptive decision-making

    Drug Alcohol Depend.

    (2014)
  • S.M. Berman et al.

    Changes in cerebral glucose metabolism during early abstinence from chronic methamphetamine abuse

    Mol. Psychiatry

    (2008)
  • A. Bischoff-Grethe et al.

    Altered reward expectancy in individuals with recent methamphetamine dependence

    J. Psychopharmacol. (Oxford)

    (2017)
  • M.M. Botvinick et al.

    Conflict monitoring and cognitive control

    Psychol. Rev.

    (2001)
  • R. Cabeza et al.

    Imaging cognition II: an empirical review of 275 PET and fMRI studies

    J. Cogn. Neurosci.

    (2000)
  • A. Chung et al.

    Decreased frontal white-matter integrity in abstinent methamphetamine abusers

    Int. J. Neuropsychopharmacol.

    (2007)
  • J.D. Cohen

    The Basics of Cognitive Control: Core Constructs and Current Considerations

    (2017)
  • R. Cools

    Role of dopamine in the motivational and cognitive control of behavior

    Neuroscientist

    (2008)
  • A.C. Dean et al.

    An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans

    Neuropsychopharmacology

    (2013)
  • T. Ernst et al.

    Evidence for long-term neurotoxicity associated with methamphetamine abuse

    Neurology

    (2000)
  • M.D. Fox et al.

    The human brain is intrinsically organized into dynamic, anticorrelated functional networks

    Proc. Natl. Acad. Sci. U. S. A.

    (2005)
  • H.-C. Fritz et al.

    Current smoking and reduced gray matter volume — a voxel-based morphometry study

    Neuropsychopharmacology

    (2014)
  • J.L. Gowin et al.

    Attenuated insular processing during risk predicts relapse in early abstinent methamphetamine-dependent individuals

    Neuropsychopharmacology

    (2014)
  • Cited by (53)

    View all citing articles on Scopus
    View full text